Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Shionogi & Co., Ltd.
  6. News
  7. Summary
    4507   JP3347200002


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Shionogi & Co Ltd : Shionogi Provides Pirespa® 200mg Tablet to ILDONG PHARMACEUTICAL for the Treatment of Idiopathic Pulmonary Fibrosis in South Korea

10/12/2012 | 03:03am EDT
Shionogi Provides Pirespa® 200mg Tablet to ILDONG PHARMACEUTICAL for the Treatment of Idiopathic Pulmonary Fibrosis in South Korea

Osaka, Japan, October 12, 2012 - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi" or "the Company") today announced that it began to supply Pirespa® 200mg tablet (generic name: pirfenidone) to ILDONG PHARMACEUTICAL Co., Ltd. (Head Office: Seoul; Chairman & CEO: Jung-chi Lee; hereafter "ILDONG") for the treatment of idiopathic pulmonary fibrosis (IPF) in South Korea from the end of September, 2012. Pirespa® is commercially available in South Korea through ILDONG since October 8, 2012.
Shionogi developed pirfenidone for the treatment of IPF in Japan after entered into the in-licensing agreement with the U.S.-based Marnac, Inc. and KDL, Inc., Tokyo in 1997. The Company received a marketing and manufacturing approval of pirfenidone for IPF in Japan in October and launched it as Pirespa® in December, 2008. It was the first time for the product to become available all over the world. Pirfenidone has a new mechanism of action which can directly inhibit fibrosis and the product is
expected to reduce the progression of IPF. The product has already been used for a lot of patients with
IPF as a new treatment option.
For the patients with IPF in South Korea, Shionogi and ILDONG entered into the licensing agreement for the sale of pirfenidone in May, 2011, and ILDONG had developed the product and received the approval after a fast track procedure as an orphan drug at the end of July, 2012. For the launch of Pirespa® by ILDONG in October, Shionogi began to provide the product to ILDONG at the end of September, 2012.
Shionogi will continue to support the treatment of patients with IPF by the stable supply of Pirespa® as well as by the provision of its accumulated clinical data in Japan, and to cooperate closely with ILDONG for the establishment of further clinical evidence of the product in Asia.

For Reference: About ILDONG PHARMACEUTICAL Co., Ltd.

Establishment: Representative: Head Office: Description of Business:
March 14, 1941
Chairman & CEO, Jung-chi Lee
60, Yangjae-dong, Seocho-gu, Seoul
ILDONG is a South Korean pharmaceutical company with the philosophy of "Excellence and Contribution to the Health and Happiness of Mankind", and which has worked to develop, produce and distribute superior
pharmaceutical products for 70 years. In particular, ILDONG is viewed as a


leading company in the production of vitamins, lactobacillus, antibiotics, and gastrointestinal preparations.

About Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis is a medical condition of unknown etiology with poor prognosis in which progressive fibrosis of the alveolar walls produces irreversible "honeycomb lung*". In general, restrictive impairment (reduction of vital capacity (VC) and total lung capacity (TLC)) is evident. As the symptom (fibrosis of the alveolar walls) progresses, gas exchange in the lungs (exchange of oxygen and carbon dioxide) becomes difficult. In some cases, oxygen therapy becomes necessary. Because of
its severity, IPF is designated as a "specified disease" (in other words, an intractable disorder).

© Publicnow 2012
All news about SHIONOGI & CO., LTD.
10/22SHIONOGI : Presents COVID-19 Therapeutic Agent Results at the ISIRV-WHO Virtual Conference
10/21SHIONOGI : Notice Regarding the Progress of Phase 2/3 Clinical Trial for New Formulation o..
10/21SHIONOGI : Japan's Shionogi starts Phase II/III clinical trial for new COVID-19 vaccine
10/20SHIONOGI : Notice Regarding the Progress of Phase 2/3 Clinical Trial for New Formulation o..
10/20SHIONOGI : Japan's Shionogi announces start of Phase II/III clinical trial for new COVID-1..
10/20Shionogi & Co., Ltd. Announces Progress of Phase 2/3 Clinical Trial for New Formulation..
10/05HITACHI : Shionogi and Hitachi Conclude a Memorandum of Understanding (MOU) for the Medium..
10/04SHIONOGI : Notice on the Selection to Apply to New Market Segment 'Prime Market' on the To..
10/04Shionogi & Co Eligible to List on Tokyo Bourse's Prime Market
10/01SHIONOGI : Notice on the Selection to Apply to New Market Segment “Prime Market&rdqu..
More news
Analyst Recommendations on SHIONOGI & CO., LTD.
More recommendations
Sales 2022 294 B 2 589 M 2 589 M
Net income 2022 104 B 917 M 917 M
Net cash 2022 331 B 2 918 M 2 918 M
P/E ratio 2022 21,6x
Yield 2022 1,47%
Capitalization 2 269 B 19 955 M 19 991 M
EV / Sales 2022 6,59x
EV / Sales 2023 5,90x
Nbr of Employees 5 485
Free-Float 87,9%
Duration : Period :
Shionogi & Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHIONOGI & CO., LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 7 527,00 JPY
Average target price 7 557,69 JPY
Spread / Average Target 0,41%
EPS Revisions
Managers and Directors
Isao Teshirogi President & Representative Director
Motozo Shiono Chairman
Teppei Mogi Independent Outside Director
Keiichi Ando Independent Outside Director
Hiroshi Ozaki Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
SHIONOGI & CO., LTD.33.58%19 955
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985